News
Johnson & Johnson is teaming up with AdoRx Therapeutics to develop lung cancer drugs. The deal gives J&J an exclusive option to research, develop and commercialize AdoRx antagonists. AdoRx ...
DUBLIN – Scottish startup Adorx Therapeutics Ltd. is the latest contender to tackle the knotty problem of immunosuppression in the tumor microenvironment through adenosine receptor inhibition. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback